文献速递免疫规划传染病防控与疫情报告

乌干达获批Subolesin抗蜱疫苗的一年随访评估

One-year follow-up evaluation of approved Subolesin anti-tick vaccine in Uganda.
PubMed 文献 · Vaccine · 2024-11-29

乌干达获批Subolesin抗蜱疫苗后,开展一年随访评估。结果显示,Mbarara和Maruzi两地接种牛抗SUB IgG抗体滴度显著升高2.1-5.0倍,疫苗有效性高于95%。Mbarara接种牛蜱总数降低0.8倍,CCHFV血清阳性牛显著减少40%。

要点

  • 接种牛抗SUB IgG抗体滴度较未接种显著升高2.1-5.0倍,疫苗有效性高于95%。
  • Mbarara接种牛蜱总数降低0.8倍,抗体滴度与蜱计数呈负相关趋势。
  • SUB接种动物CCHFV血清阳性显著减少40%,初免三剂后每年加强一剂足以维持保护性抗体滴度。

核心结论

  • 初免三剂后每年加强一剂足以维持针对蜱及蜱传疾病的保护性抗体滴度。
  • 结果对乌干达及撒哈拉以南非洲其他国家实施Subolesin抗蜱疫苗具有相关性。

研究设计与样本

  • 在乌干达Subolesin抗蜱疫苗获批后开展的一年随访评估研究。

主要发现

  • Mbarara和Maruzi接种牛抗SUB IgG抗体滴度显著升高2.1-5.0倍,疫苗有效性高于95%。
  • Mbarara接种牛蜱总数降低0.8倍,抗SUB抗体滴度与蜱计数呈负相关趋势。
  • SUB接种动物CCHFV血清阳性显著减少40%,CCHFV血清阳性牛与每头动物蜱总数呈显著正相关。
  • 抗SUB抗体滴度与CCHFV血清阳性牛呈负相关趋势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

After approval of the Subolesin-based anti-tick vaccine in Uganda, we completed a one-year follow-up evaluation study. The results showed significantly 2.1-5.0-fold higher anti-SUB IgG antibody titers in vaccinated cattle in Mbarara and Maruzi with vaccine effectiveness higher than 95 %. In Mbarara, total number of ticks were 0.8-fold lower in vaccinated cattle with a negative correlation tendency between anti-SUB antibody titers and tick counts. The CCHFV-seropositive cattle significantly decreased in 40 % in SUB-vaccinated animals with a significant positive correlation between CCHFV-seropositive cattle and the total number of ticks per animal and a negative correlation tendency between anti-SUB antibody titers and CCHFV-seropositive cattle. A boosting vaccine dose yearly after primary vaccination with three doses is sufficient to maintain protective antibody titers against ticks and tick-borne diseases affecting human and animal health. These results are relevant for implementation of anti-tick Subolesin-based vaccines in Uganda and other countries in Sub-Saharan Africa.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kasaija PD, Kabi F, Semakula J, et al. One-year follow-up evaluation of approved Subolesin anti-tick vaccine in Uganda. Vaccine. 2024. PMID: 39612805. doi:10.1016/j.vaccine.2024.126562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。